Jacob Haling

Mirati Therapeutics Inc

Claim

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 16 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

时间

引用量

主题

期刊级别

合作者

合作机构

Supplementary Table S1 from the SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading

Niranjan Sudhakar,Larry Yan,Fadia Qiryaqos,Lars D. Engstrom,Jade Laguer,Andrew Calinisan,Allan Hebbert,Laura Waters,Krystal Moya,Vickie Bowcut,Laura Vegar,John M. Ketcham,Anthony Ivetac,Christopher R. Smith,J. David Lawson,Lisa Rahbaek,Jeffrey Clarine,Natalie Nguyen,Barbara Saechao,Cody Parker, Adam J. Elliott,Darin Vanderpool,Leo He,Laura D. Hover,Julio Fernandez-Banet,Silvia Coma,Jonathan A. Pachter,Jill Hallin,Matthew A. Marx,David M. Briere,James G. Christensen,Peter Olson,Jacob Haling,Shilpi Khare

crossref（2024）

Cited0Views0Bibtex

Supplementary Figure S6 from the SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading

crossref（2024）

Cited0Views0Bibtex

Supplementary Materials and Methods from the SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading

crossref（2024）

Cited0Views0Bibtex

Supplementary Table S3 from the SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading

crossref（2024）

Cited0Views0Bibtex

Supplementary Figure S7 from the SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading

crossref（2024）

Cited0Views0Bibtex

Supplementary Table S2 from the SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading

crossref（2024）

Cited0Views0Bibtex

The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading

MOLECULAR CANCER THERAPEUTICSno. 10 (2024): 1418-1430

Cited1Views0WOSBibtex

Design and Discovery of MRTX0902, a Potent, Selective, Brain- Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction

John M. Ketcham,Jacob Haling,Shilpi Khare,Vickie Bowcut,David M. Briere,Aaron C. Burns,Robin J. Gunn,Anthony Ivetac,Jon Kuehler,Svitlana Kulyk,Jade Laguer,J. David Lawson,Krystal Moya,Natalie Nguyen,Lisa Rahbaek,Barbara Saechao,Christopher R. Smith,Niranjan Sudhakar,Nicole C. Thomas,Laura Vegar,Darin Vanderpool,Xiaolun Wang,Larry Yan,Peter Olson,James G. Christensen,Matthew A. Marx

Journal of Medicinal Chemistry（2022）

Cited49Views0WOSBibtex

Abstract LB505: Design and Discovery of MRTX0902, a Potent, Selective, and Orally Bioavailable SOS1 Inhibitor

John M. Ketcham,David M. Briere,Aaron C. Burns,James G. Christensen,Robin J. Gunn,Jacob Haling,Anthony Ivetac,Shilpi Khare,Jon Kuehler,Svitlana Kulyk,Jade Laguer, John D. Lawson,Krystal Moya,Natalie Nguyen,Peter Olson,Lisa Rahbaek,Christopher R. Smith,Niranjan Sudhakar,Nicole C. Thomas,Darin Vanderpool,Xiaolun Wang,Matthew A. Marx

Cancer Researchno. 12_Supplement (2022)

Cited0Views0Bibtex

Design and discovery of MRTX0902, a potent, selective, and orally bioavailable SOS1 inhibitor

CANCER RESEARCHno. 12 (2022)

Cited0Views0Bibtex

Author Statistics

#Papers: 0

#Citation: 0

H-Index: 0

G-Index: 0

Sociability: 0

Diversity: 0

Activity: 0

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn